Pavel Majer

pavel.majer@uochb.cas.cz

+420 220 183 125

Group leader

Drug Discovery

Pavel Majer Group

All publications

Latest publications

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

R. Rais L. Tenora M. L. Arwood A. Pal J. Alt Y. Wu J. Lam J. M. H. Aguilar L. Zhao D. E. Peters C. Tallon R. Pandey A. G. Thomas R. P. Dash T. Seiwert P. Majer R. D. Leone J. D. Powell B. S. Slusher

Science Advances 8 (46): eabq5925 (2022)

Go to the publication

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects

M. Krečmerová P. Majer R. Rais B. S. Slusher

Frontiers in Chemistry 10: 889737 (2022)

Go to the publication

Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement

J. Alt S. S. Gori K. M. Lemberg A. Pal V. Veeravalli Y. Wu J. M. H. Aguilar R. P. Dash L. Tenora P. Majer Q. Sun B. S. Slusher R. Rais

Current Drug Metabolism 22 (9): 735 - 745 (2021)

Go to the publication

Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with α-ketoamide warheads

A. Šimková T. Ormsby N. Sidej L. Poštová Slavětínská J. Brynda J. Beranová P. Šácha P. Majer J. Konvalinka

European Journal of Medicinal Chemistry 224: 113717 (2021)

Go to the publication

${ item.category }

Pavel Majer

Latest publications